Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Common Stock (NQ: TVGN )

0.8925 +0.1125 (+14.42%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tevogen Bio Holdings Inc. - Common Stock

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports First Quarter 2024 Financial Results
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant
From Tevogen Bio
Via Business Wire
Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita
From Tevogen Bio
Via Business Wire
Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI
From Tevogen Bio
Via Business Wire
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
From Tevogen Bio
Via Business Wire
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market
From Tevogen Bio
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.